low-dose il-2 Search Results


low dose interleukin (il)-2  (Chiron Corporation)
90
Chiron Corporation low dose interleukin (il)-2
Low Dose Interleukin (Il) 2, supplied by Chiron Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low dose interleukin (il)-2/product/Chiron Corporation
Average 90 stars, based on 1 article reviews
low dose interleukin (il)-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il2  (PeproTech)
90
PeproTech low-dose il2
Low Dose Il2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il2/product/PeproTech
Average 90 stars, based on 1 article reviews
low-dose il2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (PeproTech)
90
PeproTech low-dose il-2
Low Dose Il 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/PeproTech
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Biohaven Pharmaceuticals)
90
Biohaven Pharmaceuticals low-dose il-2
Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
Low Dose Il 2, supplied by Biohaven Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Biohaven Pharmaceuticals
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
subcutaneous low-dose il-2  (Olon Ricerca Bioscience)
90
Olon Ricerca Bioscience subcutaneous low-dose il-2
Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
Subcutaneous Low Dose Il 2, supplied by Olon Ricerca Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/subcutaneous low-dose il-2/product/Olon Ricerca Bioscience
Average 90 stars, based on 1 article reviews
subcutaneous low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Thoren Caging Systems)
90
Thoren Caging Systems low-dose il-2

Low Dose Il 2, supplied by Thoren Caging Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Thoren Caging Systems
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (PepTech Corporation)
90
PepTech Corporation low-dose il-2

Low Dose Il 2, supplied by PepTech Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/PepTech Corporation
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Inserm Transfert)
90
Inserm Transfert low-dose il-2

Low Dose Il 2, supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Inserm Transfert
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2  (Amgen)
90
Amgen low-dose il-2

Low Dose Il 2, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2/product/Amgen
Average 90 stars, based on 1 article reviews
low-dose il-2 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
low-dose il-2 therapy  (Siegert Wafer)
90
Siegert Wafer low-dose il-2 therapy

Low Dose Il 2 Therapy, supplied by Siegert Wafer, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/low-dose il-2 therapy/product/Siegert Wafer
Average 90 stars, based on 1 article reviews
low-dose il-2 therapy - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

Journal: International Journal of Molecular Sciences

Article Title: Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond

doi: 10.3390/ijms24010204

Figure Lengend Snippet: Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

Article Snippet: I/II , Biohaven Pharmaceuticals , Autologous memory-like NK cells with BHV-1100 (antibody recruiting molecule) and low-dose IL-2 , MM , NCT04634435.

Techniques: Ligand Binding Assay

Journal: The Cochrane Database of Systematic Reviews

Article Title: Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

doi: 10.1002/14651858.CD010248.pub2

Figure Lengend Snippet:

Article Snippet: In addition to serving as maintenance therapy, the potential role of low‐dose IL‐2 as part of consolidation immunotherapy for the maintenance of CR in AML is obvious, particularly to people in CR with a low or minimal burden of leukaemia ( Thoren 2009 ).

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

doi: 10.1002/14651858.CD010248.pub2

Figure Lengend Snippet:

Article Snippet: In addition to serving as maintenance therapy, the potential role of low‐dose IL‐2 as part of consolidation immunotherapy for the maintenance of CR in AML is obvious, particularly to people in CR with a low or minimal burden of leukaemia ( Thoren 2009 ).

Techniques: Clinical Proteomics

Journal: The Cochrane Database of Systematic Reviews

Article Title: Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

doi: 10.1002/14651858.CD010248.pub2

Figure Lengend Snippet:

Article Snippet: In addition to serving as maintenance therapy, the potential role of low‐dose IL‐2 as part of consolidation immunotherapy for the maintenance of CR in AML is obvious, particularly to people in CR with a low or minimal burden of leukaemia ( Thoren 2009 ).

Techniques: Recombinant

Journal: The Cochrane Database of Systematic Reviews

Article Title: Interleukin‐2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

doi: 10.1002/14651858.CD010248.pub2

Figure Lengend Snippet:

Article Snippet: In addition to serving as maintenance therapy, the potential role of low‐dose IL‐2 as part of consolidation immunotherapy for the maintenance of CR in AML is obvious, particularly to people in CR with a low or minimal burden of leukaemia ( Thoren 2009 ).

Techniques: